Jeremy Levin, Ovid CEO
For two years, Ovid spun a Phase II miss as a win. The drug just failed Phase III
Two years ago, Ovid’s lead program failed in Phase II. Or at least that’s what analysts said.
Jeremy Levin, the company’s CEO, argued investors misunderstood …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
